| HOME >> MEDICINE >> TECHNOLOGY |
Arizona Heart Institute Pioneers Research That May Offer New Hope to Heart Failure Patients
PHOENIX, Oct. 8 /PRNewswire/ -- Nationally, over 3,000 people are waiting for a heart transplant - and a new lease on life. Sadly, only half of those will receive a transplant. Now, pioneering research at Arizona Heart Institute (AHI) is paving the way for how to treat congestive heart failure (CHF) patients.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/ahi/35313/
Called MyoCell(R) Muscle Stem Cell Therapy, the unique transplant procedure actually uses skeletal muscle stem cells (myoblasts) from the patient's own body that are injected into the heart. This may create new functioning heart muscle.
Arizona Heart Institute has extensive knowledge in this area, having already completed two myoblast transplantation research studies in patients suffering from congestive heart failure (CHF), the first in 2002 involving the direct injection of myoblast cells into the heart during open heart surgery, and in 2004, the nation's first delivery of myoblast cells using a minimally invasive, catheter-based approach.
Results of these early-phase studies indicate myoblast therapy may improve contractility of heart muscle. Today, AHI is involved in the next stages of myoblast research with the potential to bring myoblast stem cell therapy for eligible CHF patients one step closer to commercialization.
Arizona Heart Institute is part of the MARVEL (Phase II/III Study to Assess Safety and Efficacy of Myoblast Implementation Into Myocardium Post Myocardial Infarction(s)) multicenter trial sponsored by BioHeart, Inc., to further investigate the stem cell implementation procedure.
"The MARVEL research study may lead to the future of medicine for CHF,"
said Edward B. Diethrich, the study's principal investigator at AHI,
founder and medical director
'/>"/>
| SOURCE Arizona Heart Institute Copyright©2008 PR Newswire. All rights reserved |